StockData
BioLineRx Ltd. logo

BioLineRx Ltd. (BLRX) stock

BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 3/30
$1.12−0.03 (-2.61%)

Close on Nov 17, 2026Market cap $4.87MP/E –Yield –

BioLineRx r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $8.09M, down 11.5% from the year before. Over ten years it grew -3.4% a year on average. The highest annual figure on record is $23.44M in fiscal 2019.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$8.09M-11.5%
FY2024Dec 31, 2024$9.15M-26.9%
FY2023Dec 31, 2023$12.52M-29.0%
FY2022Dec 31, 2022$17.63M-9.4%
FY2021Dec 31, 2021$19.47M+7.1%
FY2020Dec 31, 2020$18.17M-22.5%
FY2019Dec 31, 2019$23.44M+18.3%
FY2018Dec 31, 2018$19.81M+1.5%
FY2017Dec 31, 2017$19.51M+74.6%
FY2016Dec 31, 2016$11.18M-2.7%
FY2015Dec 31, 2015$11.49M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.94M-45.4%
Q2 FY2025Jun 30, 2025$2.33M-54.7%
Q2 FY2024Jun 30, 2024$2.23M-52.0%
Q2 FY2023Jun 30, 2023$3.01M-43.3%
Q2 FY2022Jun 30, 2022$5.40M+20.3%
Q2 FY2021Jun 30, 2021$5.14M+26.5%
Q2 FY2020Jun 30, 2020$4.64M–
Q2 FY2019Jun 30, 2019$5.30M–
Q2 FY2018Jun 30, 2018$4.48M–
Q2 FY2017Jun 30, 2017$4.06M–

More BioLineRx figures

See a number that looks wrong?